Cyclacel Pharmaceuticals Inc Cash Flow Conversion Efficiency
Cyclacel Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Cyclacel Pharmaceuticals Inc (CYCC) has a cash flow conversion efficiency ratio of -0.291x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.06K) by net assets ($3.63K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cyclacel Pharmaceuticals Inc (2003–2024)
Cash flow conversion efficiency of Cyclacel Pharmaceuticals Inc from 2003 to 2024. This chart illustrates how Cyclacel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cyclacel Pharmaceuticals Inc (CYCC) stock price for real-time trading data and today's change.
Cyclacel Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Cyclacel Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cyclacel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclacel Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Cyclacel Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spirent Communications plc
LSE:SPT
|
0.039x |
|
Digicontent Limited
NSE:DGCONTENT
|
0.204x |
|
SHINWON CONSTRUCTION COMPANY Ltd
KQ:017000
|
-0.084x |
|
Klaria Pharma Holding AB
ST:KLAR
|
0.004x |
|
EverGen Infrastructure Corp
V:EVGN
|
0.013x |
|
NexturnBioscience Co. Ltd
KQ:089140
|
0.019x |
|
GENENTA SCIENCE(SP.ADR)/1
F:K5F
|
N/A |
|
FACILITIES BY ADF LS-01
F:ZC8
|
N/A |
Annual Cash Flow Conversion Efficiency for Cyclacel Pharmaceuticals Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Cyclacel Pharmaceuticals Inc from 2003 to 2024. Review Cyclacel Pharmaceuticals Inc (CYCC) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.17 Million | $-7.99 Million | 3.675x | +113.85% |
| 2023-12-31 | $607.00K | $-16.11 Million | -26.544x | -2504.15% |
| 2022-12-31 | $20.43 Million | $-20.83 Million | -1.019x | -107.23% |
| 2021-12-31 | $37.69 Million | $-18.54 Million | -0.492x | -106.19% |
| 2020-12-31 | $33.26 Million | $-7.93 Million | -0.239x | +70.46% |
| 2019-12-31 | $11.70 Million | $-9.45 Million | -0.808x | -84.07% |
| 2018-12-31 | $15.27 Million | $-6.70 Million | -0.439x | -27.68% |
| 2017-12-31 | $21.77 Million | $-7.48 Million | -0.344x | +51.33% |
| 2016-12-31 | $14.27 Million | $-10.08 Million | -0.706x | +8.02% |
| 2015-12-31 | $18.84 Million | $-14.46 Million | -0.768x | +10.97% |
| 2014-12-31 | $21.69 Million | $-18.70 Million | -0.862x | -32.78% |
| 2013-12-31 | $28.02 Million | $-18.20 Million | -0.649x | +45.97% |
| 2012-12-31 | $10.02 Million | $-12.04 Million | -1.202x | -67.70% |
| 2011-12-31 | $19.50 Million | $-13.98 Million | -0.717x | -11.35% |
| 2010-12-31 | $24.92 Million | $-16.04 Million | -0.644x | +80.32% |
| 2009-12-31 | $4.64 Million | $-15.19 Million | -3.272x | -125.82% |
| 2008-12-31 | $20.64 Million | $-29.91 Million | -1.449x | -262.93% |
| 2007-12-31 | $57.97 Million | $-23.14 Million | -0.399x | -6.70% |
| 2006-12-31 | $53.92 Million | $-20.17 Million | -0.374x | +74.60% |
| 2005-12-31 | $14.60 Million | $-21.51 Million | -1.473x | -208.20% |
| 2004-12-31 | $44.12 Million | $-21.09 Million | -0.478x | -300.11% |
| 2003-12-31 | $-64.84 Million | $-15.49 Million | 0.239x | -- |
About Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more